Roche and Jazz Link Drug Combo to Improved Survival in Phase III Lung Cancer Trial
Analysts said the data suggest “a strong treatment effect.” Jazz has filed for FDA approval for the combination, which could offer an alternative to monotherapy treatments from Roche and AstraZeneca.
Roche and Jazz Link Drug Combo to Improved Survival in Phase III Lung Cancer Trial Read More »
